TABLE 2.
Funding Source for Pediatric and Adult Drug Trials
| Primary Funding Source | All Conditions (N = 2440), n (%)a | Conditions in High-Income Countries (N = 1618), n (%)a | Conditions in Middle- and Low-Income Countries (N = 1241), n (%)a | |||
|---|---|---|---|---|---|---|
| Pediatric Trials (N = 292) | Adult Trials (N = 2148) | Pediatric trials (N = 159) | Adult Trials (N = 1459) | Pediatric trials (N = 148) | Adult Trials (N = 1093) | |
| Industry | 107 (36.6) | 1106 (51.5) | 80 (50.3) | 854 (58.5) | 38 (25.7) | 461 (42.2) |
| Governmentb | 25 (8.6) | 108 (5.0) | 12 (7.6) | 60 (4.1) | 14 (9.5) | 72 (6.6) |
| Nonprofit with industry contributionc | 14 (4.8) | 284 (13.2) | 10 (6.3) | 158 (10.8) | 6 (4.0) | 176 (16.1) |
| Nonprofit without industry contributionc | 146 (50.0) | 650 (30.3) | 57 (35.8) | 387 (26.5) | 90 (60.8) | 384 (35.1) |
a
χ2 P < .001 for funding source among all conditions, P = .005 for funding source among high-income country conditions, and P < .001 for funding source among middle- and low-income country conditions.
b
Among government-funded trials, none of the pediatric trials and 6 of the adult trials also received secondary industry funding.
c
Industry contributions determined based on secondary funding sources.